Behavioral Diagnostics and Versiti Clinical Trial Solutions have partnered to provide epigenetic assays for objective smoking and alcohol exposure screening in clinical trials, aiming to improve participant risk assessment and data reliability.
The NASHnext assay, powered by GENFIT's NIS4 technology, is designed to identify patients with at-risk MASH through a blood draw ordered via the Labcorp OnDemand platform.
A new position statement warns that albumin-adjusted calcium formulas are unreliable and may lead to patient misclassification.
Researchers at MD Anderson have developed an AI-based pathology tool that predicts immunotherapy response in rare cancers by analyzing immune cell changes in biopsies, according to a Journal for ImmunoTherapy of Cancer study.
The test analyzes digital biopsy images to help predict treatment response and long-term outcomes for patients with localized prostate cancer.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
Research suggests new sequencing technologies can help labs move from tissue-level averages to cell-specific testing for precision exercise medicine.
The new service supports transplantation medicine for 13 million people across Northern California and Northern Nevada.
The company is introducing blood-based assays for tau biomarkers and a platform to automate laboratory workflows.
The noninvasive method uses paper spray and mass spectrometry to identify disease biomarkers in less than 30 seconds.
The Fleming Initiative and Cepheid have launched a 30-month study in England to compare rapid molecular and traditional culture screening for drug-resistant carbapenemase-producing Enterobacterales in hospital settings.
Bio-Rad has launched Vericheck ddPCR kits for quality control in cell and gene therapy manufacturing, offering validated workflows for mycoplasma detection, capsid analysis, and residual DNA quantification.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
The screening tool identifies specific molecules produced by gut bacteria to distinguish children with autism from typically developing peers.